ADmit Therapeutics is a biotech startup in Barcelona, Spain, focusing on the early detection of Alzheimer's disease using advanced epigenetic techniques. Their MAP-AD technology analyzes mitochondrial DNA methylation in blood samples to predict the progression of MCI to Alzheimer's dementia. With significant funding and support from various investors, the company aims to commercialize this innovative diagnostic tool in Europe and the United States.

Basic information

Country

SPAIN

Group Name

ADmit Therapeutics, S.L.

Source

Source